ReVision Optics, Inc. Finishes Phase One of FDA Clinical Trial

Published: Sep 08, 2010

LAKE FOREST, Calif.--(BUSINESS WIRE)--ReVision Optics (RVO), a leading company in the research, development and manufacture of implantable medical devices designed to assist patients that need reading glasses, announced today that it has completed enrollment and initial follow up in Phase I of its US clinical trial and has filed for expansion. The clinical trial is for the study of the PresbyLens, recently renamed Vue+, for the improvement of near vision in patients with presbyopia, the age-related loss of near vision.

Back to news